With the growing burden of metabolic disease, cardiovascular disease, and diabetes
mellitus, there is an implication for new pharmacological intervention. Sodium-glucose …

In recent years, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated
beneficial renoprotective effects, which culminated in the recent approval of their use for …

Introduction Despite significant advancements in immunosuppressive regimens and surgical
techniques, the prevalence of adverse events related to immunosuppression remains a …

There is a need for innovative pharmaceutical intervention in light of the increasing
prevalence of metabolic disease and cardiovascular disease. The kidneys' sodium-glucose …

Abstract 1 Chronic kidney disease (CKD), a global public health problem, is increasing at an
alarming rate 2 across Africa. The increasing CKD burden in this region is mainly driven by a …

Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with
chronic kidney disease (CKD), especially in end-stage renal disease (ESRD) patients and …

Introduction Cardiovascular and renal complications define the outcomes of diabetic kidney
transplant recipients (KTRs). The new diabetes medications have changed the management …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors were initially developed for
their glucose-lowering effects and have shown a modest glycaemic benefit in people with …

Kidney transplant recipients are a unique subgroup of chronic kidney disease patients due
to their single functioning kidney, immunosuppressive agent usage, and long-term …

The beneficial effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been
shown recently in numerous randomized controlled trials (RCT) and systematic reviews …